The global acute myeloid leukemia (AML) treatment market is expected to reach USD 6.29 billion by 2030, according to a new study by Grand View Research, Inc. The market is expected to expand at a CAGR of 10.6% from 2025 to 2030. Rising incidences of AML and increasing need for advanced therapeutics are attributed to factors such as genetic mutations, unhealthy lifestyles, continued exposure to hazardous chemicals such as benzene, and radiation exposure. Moreover, the increasing geriatric population base and growing unmet healthcare needs are expected to boost growth. The growing incidence of AML underscores the urgent need for innovative therapies. According to the American Cancer Society, approximately 22,010 individuals are estimated to be diagnosed with AML in 2025, further highlighting the rising demand for effective treatment options. Advancements in targeted therapies have been at the forefront of the progress in AML treatment so far. In recent years, there has been substantial development in therapies such as BCL2 inhibitors, IDH inhibitors, and FLT3 inhibitors. These therapies provide personalized treatment options tailored to specific genetic mutations, resulting in improved outcomes for patients.
Combinations such as venetoclax with azacitidine or other hypomethylating agents have shown promising results in enhancing survival rates for AML patients. Additional research interest focuses on incorporating venetoclax into the traditional 7+3 chemotherapy regimen, which aims to maximize treatment efficacy.
Moreover, the exploration of immunotherapies, including CAR-T cell therapies, represents a transformative trend in AML treatment. These therapies are designed to bolster the immune system’s response to cancer cells, thus providing new hope for patients who have limited options. The advancements in the understanding of genetic mutations associated with AML have further contributed to personalized treatment strategies, such as targeting specific mutations such as KMT2A and NPM1 with menin inhibitors.
Get deeper insights, latest developments & key market drivers in the Global Acute Myeloid Leukemia Treatment Market
Key Acute Myeloid Leukemia Treatment Company Insights
Some key companies operating in the market include Astellas Pharma Inc.; Bristol-Myers Squibb Company; DAIICHI SANKYO COMPANY, LIMITED; among others. The market is characterized by a dynamic competitive landscape, with pharmaceutical giants, biotechnology innovators, diagnostics companies, and healthcare institutions vying for market share-pharmaceuticals who are launching innovative targeted therapies, immunotherapies, and personalized treatments.
• Bristol-Myers Squibb Company provides Onureg (azacitidine), an oral maintenance therapy approved for adult patients in complete remission.
• Jazz Pharmaceuticals plc offers Vyxeos (daunorubicin and cytarabine), a liposomal formulation approved for newly diagnosed therapy-related AML or AML with myelodysplasia-related changes.
Looking for Acute Myeloid Leukemia Treatment Market Report? Get your free sample PDF with key data & latest trends.
Key questions answered in this report
• How big is the market?
• What is the market growth?
• Which segment accounted for the largest market share?
• Who are the key players in market?
• What are the factors driving the market?